Last reviewed · How we verify
SL-28.
At a glance
| Generic name | SL-28. |
|---|---|
| Sponsor | Second Life Therapeutics |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SL-28 for Advanced Solid Tumours (PHASE1, PHASE2)
- Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SL-28. CI brief — competitive landscape report
- SL-28. updates RSS · CI watch RSS
- Second Life Therapeutics portfolio CI